A Phase 2 Randomized, Double Blind, Placebo-Controlled, Multiple Ascending dose study to evaluate Safety,Efficacy, and Pharmacokinetics and Pharmacodynamics of PF 06252616 in Ambulatory boys with Duchenne Muscular Dystrophy.

Administered By

Awarded By

Contributors

Start/End

  • December 1, 2014 - June 30, 2019